Author: Gábor Winkler
View More View Less
  • 1 Fővárosi Szent János Kórház II. Belgyógyászat-Diabetológia Budapest Diós árok 1–3. 1125
  • | 2 Miskolci Egyetem, Egészségügyi Kar Elméleti Egészségtudományi Intézet Miskolc
Restricted access

A szulfanilureavegyületek hosszú ideje a 2-es típusú diabetes vércukorcsökkentő kezelésének alapgyógyszerei. Az inkretin mechanizmusú antidiabetikumok megjelenésével azonban időről időre felmerül, van-e helye továbbra is e gyógyszercsoportnak napjaink terápiájában. A szerző áttekinti a szulfanilureák általános hatástani jellemzőit, s a Magyarországon forgalomban lévő második generációs származékok főbb sajátosságait. Kitér az inkretin hatású szerek, elsősorban a dipeptidil-peptidáz-gátlók és a szulfanilureák különbségeire. Megállapítja, hogy amint azt a legújabb kezelési irányelvek is tükrözik, a szulfanilureáknak ma is helye van a vércukorcsökkentő kezelésben, bár az inzulinszekretagóg szerek között a korábbinál hátrébb szorultak. Rendelésük esetén fontos a megfelelő készítményválasztás – rendezett vesefunkció esetén elsősorban gliclazid vagy glimepirid adása −, a cukorbeteg megfelelő edukálása, valamint a kívánt anyagcserehatást biztosító legkisebb dózis választása. Orv. Hetil., 2015, 156(13), 511–515.

  • Del Prato, S., Pulizzi, N.: The place of sulfonylureas in the therapy for type 2 diabetes mellitus. Metabolism, 2006, 55(Suppl. 1), S20–S27.

  • Makkar, B. M., Gupta, D., Gainda, A.: Clinical trials to clinical practice: role of sulfonylureas in today’s practice. In: Muruganathan, A. (ed.): Medicine Update, Vol. 23, 2013, Chapter 87, 393–398. www.apiindia.org/medicine_update_2013

  • Abrahamson, M. J.: Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? Yes, they continue to serve us well! Diabetes Care, 2015, 38(1), 166–169.

  • Kalra, S., Gupta, Y.: Sulfonylureas. Recent Advances in Endocrinology, 2015, 65(1), 101–104.

  • Winkler, G.: The place of sulphonylurea compounds in the blood glucose lowering therapy of type 2 diabetes. [A szulfanilureák helye a 2-es típusú diabetes vércukorszint-csökkentő kezelésében.] Lege Artis Medicinæ, 2011, 21(5), 345–349. [Hungarian]

  • Gribble, F. M., Reimann, F.: Sulphonylurea action revisited: the post-cloning area. Diabetologia, 2003, 46(7), 875–891.

  • Karagiannis, T., Paschos, P., Paletas, K., et al.: Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ, 2012, 344, e1369.

  • Li, Y., Hu, Y., Ley, S. H., et al.: Sulfonylurea use and incident cardiovascular disease among patients with type 2 diabetes: prospective cohort study among women. Diabetes Care, 2014, 37(11), 3106–3113.

  • Monami, M., Genovese, S., Mannucci, E.: Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes. Metab., 2013, 15(10), 938–953.

  • Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., et al.: Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 2012, 35(6), 1364–1379.

  • UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998, 352(9131), 837–853. Erratum: Lancet, 1999, 354(9178), 602.

  • Holman, R. R.: Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective. Metabolism, 2006, 55(Suppl. 1), S2–S5.

  • Fowler, M. J.: Diabetes treatment, Part 2: Oral agents for glycemic management. Clin. Diabetes, 2007, 25(4), 131–134.

  • The ADVANCE Collaborative Group: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med., 2008, 358(24), 2560–2572.

  • Hassanein, M., Abdallah, K., Schweizer, A.: A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study. Vasc. Health Risk. Manag., 2014, 10, 319–326.

  • Schramm, T. K., Gislason, G. H., Vaag, A., et al.: Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur. Heart J., 2011, 32(15), 1900–1908. Erratum: Eur. Heart J., 2012, 33(10), 1183.

  • Sarkar, A., Tiwari, A., Bhasin, P. S., et al.: Pharmacological and pharmaceutical profile of gliclazide: a review. J. Appl. Pharmaceutical Sci., 2011, 1(9), 11–19.

  • Winkler, M., Stephan, D., Bieger, S., et al.: Testing the bipartite model of the sulfonylurea receptor binding site: binding of A-, B-, and A+B-site ligands. J. Pharmacol. Exp. Ther., 2007, 322(2), 701–708.

  • Winkler, G.: The use of gliclazide in individualized solfonylurea therapy. [A gliclazid használata a differenciált szulfanilureaalkalmazás tükrében.] Orv. Hetil., 2014, 155(14), 541–548. [Hungarian]

  • Jarrard, R. E., Wang, Y., Salyer, A. E., et al.: Potentiation of sulfonylurea action by an EPAC-selective cAMP analog in INS-1 cells: comparison of tolbutamide and gliclazide, and a potential role for EPAC activation of a 2-APB-sensitive Ca2+ influx. Mol. Pharmacol., 2013, 83(1), 191–205.

  • Holz, G. G., Chepurny, O. G., Leech, C. A.: Epac2A makes a new impact in β-cell biology. Diabetes, 2013, 62(8), 2665–2666.

  • Kai, A. K., Lam, A. K., Chen, Y., et al.: Exchange protein activated by cAMP 1 (Epac1)-deficient mice develop β-cell dysfunction and metabolic syndrome. FASEB J., 2013, 27(10), 4122–4135.

  • Herbst, K. J., Coltharp, C., Amzel, L. M., et al.: Direct activation of Epac by sulfonylurea is isoform selective. Chem. Biol., 2011, 18(2), 243–251.

  • O’Brien, R. C., Luo, M., Balázs, N., et al.: In vitro and in vivo antioxidant properties of gliclazide. J. Diab. Compl., 2000, 14(4), 201–206.

  • Sena, C. M., Louro, T., Matafome, P., et al.: Antioxidant and vascular effects of gliclazide in type 2 diabetic rats fed high-fat diet. Physiol. Res., 2009, 58(2), 203–209.

  • Räkel, A., Renier, G., Roussin, A., et al.: Beneficial effects of gliclazide modified release compared with glibenclamide on endothelial activation and low-grade inflammation in patients with type 2 diabetes. Diabetes Obes. Metab., 2007, 9(1), 127–129.

  • Chen, L. L., Yu, F., Zheng, T. S., et al.: Effects of gliclazide on endothelial function in patients with newly diagnosed type 2 diabetes. Eur. J. Pharmacol., 2011, 659(2–3), 296–301.

  • Jennings, P. E.: Vascular benefits of gliclazide beyond glycemic control. Metabolism, 2000, 49(10 Suppl. 2), 17–20.

  • Del Guerra, S., D’Aleo, V., Lupi, R., et al.: Effects of exposure of human islet beta-cells to normal and high glucose levels with or without gliclazide or glibenclamide. Diabetes Metab., 2009, 35(4), 293–298.

  • Schernthaner, G., Grimaldi, A., DiMario, U., et al.: GUIDE Study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur. J. Clin. Invest., 2004, 34(8), 535–542.

  • Skyler, J. S., Bergenstal, R., Bonow, R. O., et al.: Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE and VA Diabetes Trials. A Position Statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J. Am. Coll. Cardiol., 2009, 53(3), 298–304.

  • Zoungas, S., Chalmers, J., Kengne, A. P., et al.: The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial. Diabetes Res. Clin. Pract., 2010, 89(2), 126–133.

  • Al Sifri, S., Basiounny, A., Echtay, A., et al.: The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial. Int. J. Clin. Pract., 2011, 65(11), 1132–1140.

  • Aravind, S. R., Ismail, S. B., Balamurugan, R., et al.: Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study. Curr. Med. Res. Opin., 2012, 28(8), 1289–1296.

  • Harrower, A.: Gliclazide modified release: from once-daily administration to 24-hour blood glucose control. Metabolism, 2000, 49(10 Suppl. 2), 7–11.

  • Gore, M. O., McGuire, D. K.: Resolving drug effects from class effects among drugs for type 2 diabetes mellitus: more support for cardiovascular outcome assessments. Eur. Heart J., 2011, 32(15), 1832–1834.

  • Zhang, Y., McCoy, R. G., Mason, J. E., et al.: Second-line agents for glycemic control for type 2 diabetes: are newer agents better? Diabetes Care, 2014, 37(5), 1338–1345.

  • Saisho, Y.: Importance of beta cell function for the treatment of type 2 diabetes. J. Clin. Med., 2014, 3(3), 923–943.

  • Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., et al.: Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2015, 38(1), 140–149.

All Time Past Year Past 30 Days
Abstract Views 95 95 6
Full Text Views 10 1 0
PDF Downloads 6 2 0